NAD+ Is the Coenzyme That Powers Both Energy Metabolism and DNA Repair — and It Declines by Approximately 50% by Age 50, Simultaneously Depriving Sirtuins of Their Required Substrate and Reducing Cellular Capacity for PARP-Mediated DNA Repair: NMN and NR Are Precursors That Raise NAD+ in Humans, but the Clinical Longevity Evidence in Humans Remains Nascent While Mouse Data Is Compelling
Updated: June 2026NAD+ · NAD plus · NAD supplement · NAD+ supplement · NAD+ aging · NAD+ decline · NAD+ levels · NAD+ age · NAD+ age decline · NMN · NMN supplement · NMN nicotinamide mononucleotide · NMN aging · NMN longevity · NMN anti-aging · NMN vs NR · NMN or NR · which is better NMN or NR · NMN nicotinamide riboside comparison · NR · NR supplement · NR nicotinamide riboside · nicotinamide riboside · nicotinamide riboside supplement · Tru Niagen · nicotinamide riboside Elysium · NAD+ sirtuin · sirtuin NAD+ · SIRT1 · SIRT1 NAD · SIRT3 · SIRT3 NAD · SIRT6 · sirtuin longevity · sirtuin aging · sirtuins David Sinclair · David Sinclair NAD · David Sinclair NMN · David Sinclair Lifespan · Sinclair NMN mouse · Sinclair NAD+ aging · Sinclair sirtuins · NAD+ Sinclair · Guarente NAD · Leonard Guarente NR · Guarente nicotinamide riboside · Guarente 2013 NR trial · NAMPT · NAMPT rate limiting · NAMPT enzyme · NAMPT NAD biosynthesis · NAMPT salvage pathway · NAD salvage pathway · NAD biosynthesis pathway · de novo NAD synthesis · tryptophan NAD · tryptophan kynurenine NAD · Preiss-Handler pathway · NAD metabolomics · blood NAD · muscle NAD · intracellular NAD · NAD+ oral bioavailability · does NMN work · does NR work · NMN human trial · NR human trial · Yoshino 2021 NMN · Yoshino Science NMN · NMN muscle · NMN insulin sensitivity · NMN older women · PARP · PARP DNA repair · PARP NAD · PARP1 NAD · DNA repair NAD · NAD DNA damage · CD38 NAD · CD38 NADase · CD38 inhibitor · CD38 apigenin · apigenin CD38 · quercetin CD38 · NAD+ and exercise · exercise NAD · exercise NAMPT · NAD+ mitochondria · mitochondria NAD · NAD oxidative phosphorylation · NAD+ energy · ATP NAD · NADH · NADH NAD ratio · NAD+ redox · NAD+ insulin resistance · NAD+ metabolic syndrome · NAD+ neuroprotection · NAD+ brain · NMN brain · NAD+ cognitive function · niacinamide NAD+ · niacin flush · niacin NAD+ · nicotinamide NAD · NMN form · NMN dose · NMN dosage · NMN 250mg · NMN 500mg · NMN 1g · NMN sublingual · NMN liposomal · NMN riboside · NR dose · NR dosage · NR 300mg · NR 500mg · NR 1g · Chromadex NR · Elysium Basis NR · NAD+ precursor comparison · tryptophan NAD+ · B3 NAD+ · niacinamide NAD+ comparison
NAD+ (nicotinamide adenine dinucleotide) exists in all living cells as both the oxidized form (NAD+) and reduced form (NADH). In the context of energy metabolism, NAD+ acts as an electron carrier in the Krebs cycle and oxidative phosphorylation — it accepts electrons (becoming NADH) and transfers them to the mitochondrial electron transport chain, driving ATP synthesis. Without adequate NAD+, this process cannot operate efficiently. In the context of longevity biology, NAD+ is the required substrate for two classes of enzymes that have attracted significant scientific attention: sirtuins (SIRT1–7, a family of NAD+-dependent deacylases associated with stress resistance, autophagy, DNA repair, and metabolic regulation) and PARPs (poly-ADP-ribose polymerases, enzymes that detect and repair DNA strand breaks by consuming NAD+).
The age-related decline in NAD+ — approximately 50% reduction between age 30 and 60 in most tissue measurements — creates a dual problem: less NAD+ for energy metabolism (contributing to the bioenergetic decline associated with aging) and less NAD+ for sirtuin and PARP activity (potentially reducing stress resistance and DNA repair capacity). The hypothesis that NAD+ supplementation could slow or partially reverse aging by restoring this substrate pool is scientifically credible and actively investigated, though human clinical evidence for longevity outcomes specifically remains limited to surrogate markers and relatively short trials.
−50%
NAD+ by age 50 — NAD+ tissue concentrations decline progressively with age; the magnitude of decline varies by tissue type: blood/PBMCs: approximately 50% reduction between age 30–60 (most measured compartment); liver: ~50–60% decline with age in mouse studies; skeletal muscle: ~30–40% decline; brain: estimated similar to muscle (~30–40%); the mechanisms of age-related NAD+ decline are multiple: reduced expression of NAMPT (the rate-limiting enzyme in the salvage pathway — see below) with aging; increased NAD+ consumption by PARP enzymes (which are activated by accumulated DNA damage — a feedback loop where more DNA damage with age → more PARP activation → more NAD+ consumed → less NAD+ available for sirtuins → reduced stress resistance → more damage); upregulation of CD38 (an NADase — an enzyme that degrades NAD+) with age; CD38 is expressed on immune cells and stromal cells, and its expression increases with the chronic low-grade inflammation of aging ("inflammaging") — creating another feedback loop; sterile inflammation → CD38 upregulation → NAD+ degradation → reduced sirtuin activity → reduced anti-inflammatory capacity → more inflammation; the CD38 connection is why reducing chronic inflammation is considered an indirect NAD+ restoration strategy; proposed CD38 inhibitors to slow NAD+ degradation: apigenin (flavonoid, ~30–40μM for CD38 inhibition in vitro), quercetin — though human pharmacological data at physiological doses is limited
NAMPT
the rate-limiting step — NAD+ is synthesized through three main pathways: DE NOVO synthesis: from tryptophan → kynurenine → quinolinate → NMN → NAD+ (via the Preiss-Handler pathway); this is the only pathway that creates new NAD+ from non-NAD+ precursors; highly energetically expensive (~60 ATP equivalents per NAD+ molecule); SALVAGE PATHWAY (primary pathway in most tissues): nicotinamide (NAM) → NMN → NAD+; this recycles the nicotinamide released when NAD+ is consumed by sirtuins and PARPs; NAMPT (nicotinamide phosphoribosyltransferase) catalyzes the conversion of NAM → NMN — this is the rate-limiting, regulated step; NAMPT expression and activity are reduced with age; this is mechanistically why aging → lower NAD+ even when precursor availability is adequate; NR PATHWAY: nicotinamide riboside (NR) → NMN → NAD+; NR enters cells via nucleoside transporters and is converted to NMN by NR kinase (NRK1/2); this is the pathway activated by NR supplementation; NMN PATHWAY: NMN → NAD+; debate exists about whether NMN enters cells directly or must first be converted to NR extracellularly and then re-enter as NR; recent evidence: Irie et al. 2020 (Nature Metabolism): a dedicated NMN transporter (Slc12a8) was identified in mouse small intestine that imports NMN directly — suggesting intestinal NMN uptake is at least partially direct; this matters for oral bioavailability claims; the practical implication: all the supplementable precursors (nicotinamide, NR, NMN) enter at different points of the salvage pathway, but all eventually raise NAD+ in tissues
Yoshino 2021
Science
the pivotal NMN human RCT — Yoshino et al. 2021 (Science): the most important human NMN trial to date; N=25 postmenopausal women with prediabetes or overweight; double-blind RCT; NMN 250mg/day for 10 weeks vs placebo; primary findings: blood NAD+ increased significantly in the NMN group (whole blood NAD+ measurement); however: skeletal muscle NAD+ did NOT increase significantly with NMN supplementation; muscle NAD+ is considered more functionally relevant than blood NAD+ (muscles are the largest NAD-consuming tissue and decline most with aging); NMN 250mg/day improved muscle insulin sensitivity in a subset analysis; the muscle NAD+ finding was surprising given that mouse studies consistently show NMN increases muscle NAD+; possible explanation: NAMPT is the rate-limiting step in muscle — if NAMPT activity is low, providing more NMN (downstream of NAMPT) may not overcome the bottleneck; higher doses of NMN might be needed; the question of whether oral NMN meaningfully raises tissue NAD+ at commercially available doses (250–500mg) in humans remains the most contested issue in the field; Elysium BASIS NR trials: Conze et al. 2019: NR 250–1,000mg/day dose-dependently increased whole blood NAD+ in healthy adults; NR appears to reliably raise blood NAD+; tissue-specific data is limited; the Guarente NR work: Leonard Guarente (MIT, co-discoverer of sirtuins) founded Elysium Health; the NR studies from his group consistently show blood NAD+ increases; functional longevity outcomes in humans remain the missing piece
Sirtuins
the longevity enzymes — sirtuins (SIRT1–7) are NAD+-dependent deacylases discovered as longevity genes in yeast (Sir2 — Silent Information Regulator 2); their human homologues are associated with stress resistance, metabolic adaptation, and longevity signaling; SIRT1 (nuclear): deacetylates PGC-1α → mitochondrial biogenesis; deacetylates FOXO transcription factors → stress resistance; activates autophagy; deacetylates p53 → reduced apoptosis under mild stress; activated by caloric restriction and resveratrol (contested); requires NAD+; SIRT3 (mitochondrial): deacetylates and activates key Krebs cycle and electron transport enzymes; reduces mitochondrial ROS production; SIRT3 knockout mice show accelerated aging phenotypes; SIRT6 (nuclear): telomere maintenance; DNA double-strand break repair; metabolic regulation; reduced with age → accelerated DNA damage; overexpression extends lifespan in male mice (Kanfi 2012); SIRT1 and caloric restriction: the NAD+-sirtuin pathway is one of the primary proposed mechanisms by which caloric restriction extends lifespan — caloric restriction → increased NAD+:NADH ratio (more oxidized) → more SIRT1 activity → downstream metabolic adaptations; the resveratrol-SIRT1 controversy: early papers claimed resveratrol directly activated SIRT1; subsequent work showed this was a fluorophore artifact; resveratrol may indirectly activate SIRT1 by inhibiting phosphodiesterases → cAMP → AMPK → increased NAD+ → SIRT1 activation; the direct activation claim is no longer accepted; the NMN mouse data: de Picciotto 2016 (Cell Metabolism): NMN supplementation in aging mice improved vascular health and exercise capacity; Mills 2016 (Cell Metabolism): NMN in aging mice improved energy metabolism, insulin sensitivity, bone density, eye function, and immune function; none of these studies showed lifespan extension — they showed healthspan improvement in aging mice
Want the full evidence writeup?
The Stack Protocol builds four complete goal stacks — Energy, Focus, Sleep, Longevity — with exact doses, timing, budget tiers, and a 30-day rollout plan, graded with the same evidence framework behind this page.
Get the Stack Protocol → $19
NAD+ Precursors: Comparative Overview
| Precursor | Entry Point | Blood NAD+ (Human) | Muscle NAD+ (Human) | Dose Range | Cost/Month |
|---|
| NMN | NMN → NAD+ (direct or via NR) | Increases significantly | Yoshino 2021: no sig. increase at 250mg | 250–1,000mg/day | $30–80 |
| NR (nicotinamide riboside) | NR → NMN → NAD+ | Dose-dependent increase (Conze 2019) | Limited data; likely similar to NMN | 250–1,000mg/day | $40–100 |
| Nicotinamide (NAM) | Direct salvage pathway entry | Increases NAD+; but may inhibit sirtuins at high doses | Some evidence | 250–500mg/day | $5–15 |
| Niacin (flush form) | Preiss-Handler pathway | Increases NAD+ | Evidence in some conditions | 15–500mg/day | $5–20 |
| Tryptophan (food) | De novo synthesis (inefficient) | Minimal NAD+ contribution | Minimal | N/A (dietary) | N/A |
NAD+ Optimization Protocol — Evidence-Based Approach
Foundational (before considering supplements): the most robust way to raise NAD+ without supplements is through lifestyle interventions that increase NAMPT expression and reduce NAD+ consumption by CD38: EXERCISE: resistance training and HIIT both increase skeletal muscle NAMPT expression → more efficient NAD+ biosynthesis; the exercise-NAMPT relationship is one reason fit older adults have better NAD+ levels than sedentary peers; CALORIC RESTRICTION / INTERMITTENT FASTING: raises NAD+:NADH ratio by reducing caloric throughput; reduces CD38 by reducing inflammation; fasting periods of 12–16 hours are sufficient to produce measurable NAD+ ratio shifts; REDUCE CHRONIC INFLAMMATION: the CD38 NADase upregulation by chronic inflammation is a major age-related NAD+ sink; anti-inflammatory diet (Mediterranean-style), omega-3s, reducing processed food → less CD38 → less NAD+ degradation; MINIMIZE ALCOHOL: ethanol metabolism consumes NAD+ heavily in the liver (alcohol → acetaldehyde → acetate both require NAD+ as cofactor) — chronic alcohol use significantly depletes hepatic NAD+.
Supplementation approach: NR or NMN are biochemically equivalent entry points with minor pharmacokinetic differences that are not definitively resolved in humans; choose based on cost and form preference; NR 300–500mg/day OR NMN 250–500mg/day; take in the morning (NAD+ metabolism is circadian — morning supplementation aligns with peak NAMPT activity); evidence for doses above 500mg/day is limited; the incremental benefit above 500mg is unclear; pairing with apigenin (parsley, chamomile) as a CD38 inhibitor is biologically rational but lacks human clinical data; CAUTION: nicotinamide (plain NAM) at high doses (>500mg/day) may inhibit sirtuins directly (sirtuin inhibition by nicotinamide is well-documented in vitro — it is a product inhibitor); this is why niacinamide/NAM is not the preferred NAD+ precursor for longevity purposes despite being cheaper and better absorbed; the 5-year view: human longevity outcomes data from ongoing NR/NMN trials expected 2025–2028; watch for BIOMICS, IAMHEALTHY, and other registered NAD+ intervention trials for definitive functional data.
NMN 500mg →
Nicotinamide Riboside →
More longevity supplement guides
As an Amazon Associate, StackProtocol earns from qualifying purchases made through links on this page. This does not affect the price you pay.